Orthocell (ASX:OCC) - Managing Director, Paul Anderson (left)
Managing Director, Paul Anderson (left)
Source: Orthocell
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Regenerative medicine company Orthocell (OCC) secures Chinese and New Zealand patents for its novel CelGro collagen medical device 
  • The patents, titled “Sutureless repair of soft tissue”, are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe
  • The patents are set to expire on 12 October 2035
  • Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.

The patents, titled “Sutureless repair of soft tissue,” are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe.

Sutureless repair of soft tissue means repairing damaged soft tissue without the use of damaging stitches.

Orthocell said sutureless repair had the potential to greatly improve the efficiency of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue caused by the use of stitches.

Orthocell’s patented method of sutureless repair involves the use of CelGro, the company’s resorbable collagen medical device. CelGro acts as a cell scaffold when implanted at the site of tissue injury, encouraging new cell growth. Cells from the regenerating tissue integrate with the collagen fibres to guide tissue regeneration.

“These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair,” Orthocell Managing Director Paul Anderson said.

“This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, European Union and Australia.”

The patents are set to expire on 12 October 2035.

Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST.


OCC by the numbers
More From The Market Online

Universal Biosensors surges 60% on FDA approval for Class II device

Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical…

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…